Ocugen, Inc. Financial Summary

Quick Answer

Ocugen, Inc. reported Total Revenue of $4.41 million for fiscal year 2025.

Ocugen, Inc. — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $4.41M
+8.8%
$4.05M
-32.8%
$6.04M
+142.6%
$2.49M $0.00
-100.0%
$43.0K
Revenue (ASC 606) $4.41M
+8.8%
$4.05M
-32.8%
$6.04M
+142.6%
$2.49M
Net Income -$67.85M
-25.5%
-$54.05M
+14.3%
-$63.08M
+27.3%
-$86.80M
-48.7%
-$58.37M
-167.5%
-$21.82M
-7.8%
Diluted EPS -$0.26
+35.0%
-$0.40
-33.3%
-$0.30
+3.2%
-$0.31
+78.8%
Total Assets $43.52M
-47.2%
$82.44M
-14.4%
$96.30M
-32.1%
$141.73M
+34.0%
$105.76M
+286.3%
$27.38M
+62.9%
Cash and Equivalents $68.26M
-47.4%
$129.77M
+36.7%
$94.96M
+295.0%
$24.04M
+222.9%
Long-Term Debt $27.54M
+0.7%
$27.34M
+2484.6%
$1.06M
-38.9%
$1.73M
+1.1%
$1.71M
-6.1%
$1.82M
+70.0%
Stockholders Equity -$12.17M
-141.1%
$29.63M
-54.3%
$64.90M
-48.3%
$125.52M
+37.6%
$91.20M
+323.2%
$21.55M
+95.6%
R&D Expense $39.75M
+23.7%
$32.13M
-18.8%
$39.57M
Operating Income -$62.92M
-14.9%
-$54.76M
+16.4%
-$65.53M
+26.4%
-$89.07M
-53.5%
-$58.03M
-172.6%
-$21.29M
-50.3%
Shares Outstanding 312.38M
+7.2%
291.37M
+13.6%
256.57M
+15.8%
221.60M
+11.1%
199.38M
+8.4%
184.01M
+249.7%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $1.75M +54.2% +27.6%
Revenue (ASC 606) September 30, 2025 $1.75M +54.2% +27.6%
Net Income September 30, 2025 -$20.05M -54.6% -36.0%
Diluted EPS June 30, 2024 -$0.04 +60.0% +20.0%
Total Assets September 30, 2025 $57.60M -7.0% +7.5%
Cash and Equivalents June 30, 2024 $15.70M -77.8% -40.5%
Long-Term Debt September 30, 2025 $28.40M +1707.8% +1.3%
Stockholders Equity September 30, 2025 $3.53M -91.3% +15.8%
R&D Expense September 30, 2025 $11.15M +37.5% +32.7%
Operating Income September 30, 2025 -$17.62M -33.0% -27.8%
Shares Outstanding September 30, 2025 312.32M +7.6% +6.9%
  • Ocugen, Inc. reported Total Revenue of $4.41 million for fiscal year 2025.
  • Ocugen, Inc. showed an increase of +8.8% in Total Revenue compared to the prior fiscal year.
  • Ocugen, Inc. reported Revenue (ASC 606) of $4.41 million for fiscal year 2025.
  • Ocugen, Inc. showed an increase of +8.8% in Revenue (ASC 606) compared to the prior fiscal year.
  • Ocugen, Inc. reported Net Income of -$67.85 million for fiscal year 2025.
  • Ocugen, Inc. showed a decrease of -25.5% in Net Income compared to the prior fiscal year.
  • Ocugen, Inc. reported Diluted EPS of $0.26 per share (loss) for fiscal year 2023.
  • Ocugen, Inc. showed an increase of +35.0% in Diluted EPS compared to the prior fiscal year.
  • Ocugen, Inc. reported Total Assets of $43.52 million for fiscal year 2025.
  • Ocugen, Inc. showed a decrease of -47.2% in Total Assets compared to the prior fiscal year.
  • Ocugen, Inc. reported Cash and Equivalents of $39.46 million for fiscal year 2023.
  • Ocugen, Inc. showed a decrease of -26.2% in Cash and Equivalents compared to the prior fiscal year.
  • Ocugen, Inc. reported Long-Term Debt of $27.54 million for fiscal year 2025.
  • Ocugen, Inc. showed an increase of +0.7% in Long-Term Debt compared to the prior fiscal year.
  • Ocugen, Inc. reported Stockholders Equity of -$12.17 million for fiscal year 2025.
  • Ocugen, Inc. showed a decrease of -141.1% in Stockholders Equity compared to the prior fiscal year.
  • Ocugen, Inc. reported R&D Expense of $39.75 million for fiscal year 2025.
  • Ocugen, Inc. showed an increase of +23.7% in R&D Expense compared to the prior fiscal year.
  • Ocugen, Inc. reported Operating Income of -$62.92 million for fiscal year 2025.
  • Ocugen, Inc. showed a decrease of -14.9% in Operating Income compared to the prior fiscal year.
  • Ocugen, Inc. reported Shares Outstanding of 312.38 million shares for fiscal year 2025.
  • Ocugen, Inc. showed an increase of +7.2% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment